The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

After an abnormal NIPT finding in a pregnant woman, a maternal-fetal medicine doctor orders a second NIPT, against ...

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

A legislative ban on pharma ads, a tool for companies to amplify messaging on drugs, including for precision medicines, is ...

The study also included older children and found the best outcomes in patients between 5 years and 8 years old.

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

D Molecular Therapeutics said it is streamlining operations to offset expected expenses as it accelerates the timelines for its Phase III trials.

Rutgers New Jersey Medical School has rolled out routine blood tests for the cardiovascular biomarker at another one of its ...